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From summary and commentary
In 2013 nalmefene was authorised for
moderating drinking among patients not in need
of detoxification, extending pharmacotherapy to
less dependent drinkers.
The featured review examined whether other
medications (naltrexone, acamprosate, baclofen,
and topiramate) have been found to do this just
as well among non-detoxified patients with an
alcohol use disorder.
There was no high quality evidence for any the
medications, though nalmefene, topiramate and
baclofen have been found to reduce consumption,
and topiramate also consistently reduced other
measures of drinking. No evidence was found
that nalmefene was superior to the other
medications, or that any improved health.
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In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification,
extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this
review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none
was there high quality evidence.
SUMMARY This review effectively assessed a range of medications for roughly the purposes for which
nalmefene was granted marketing authorisation in Europe and approval in the UK – to help reduce
consumption in alcohol-dependent adults who do not have physical withdrawal symptoms and do not require
immediate detoxification, rather than as part of a treatment intended to sustain abstinence in detoxified
patients.
Nalmefene’s parent drug, naltrexone, is approved for
maintaining abstinence, but has also been prescribed
‘off-label’ to moderate consumption. Other drugs acting on
neural networks driven by the neurotransmitter gamma-
aminobutyric acid have been studied for this purpose,
including baclofen and acamprosate and the anti-epileptic
topiramate. Widely disseminated guidelines and major
reviews now promote medications to help moderate
drinking as part of a harm-reduction strategy.
The featured review aimed to assess the efficacy of this
approach in general, and the relative efficacy of the
different medications, by amalgamating findings from
head-to-head comparisons between these and from indirect
comparisons via studies which have, for example, compared
drug A and drug B with a placebo, but in different trials –
so-called ‘network’ analysis.
An attempt was made to limit the selection of trials to
non-abstinent patients who have not completed
detoxification. As this is usually completed after five to
seven days, trials were included which recruited patients
abstinent for less than five days. Excluded were trials which stipulated longer abstinence periods or prior
detoxification, and those which selected patients also suffering physical or psychological comorbidity.
To help eliminate bias, the trials had to have randomly allocated adult patients with a diagnosis of alcohol use
disorders (including dependence) to one of the medications versus another medication, and/or versus an
inactive placebo. Reports in English, French, German and Spanish were considered, retrieved in searches
conducted up to June 2016. Unpublished studies and those conducted for pharmaceutical companies were also
sought.
Of primary interest was the medications’ impacts on total alcohol consumption, stemming from the rationale
that if medications reduce consumption, they also correspondingly reduce alcohol-related harm. However,
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other consumption outcomes were assessed, as were indications of the safety of the medications.
In the event, all 32 trials included in the amalgamation of results compared the medications with a
placebo rather than with each other. Published between 1994 and 2015, nine compared of nalmefene
with placebo, 14 naltrexone, four each baclofen and topimarate, and just one acamprosate. Except for
one nalmefene and one naltrexone trial, all patients were offered psychological support (including
medical management programmes) during the study periods.
Due to possible or actual loss to follow-up, 26 of the 32 studies were vulnerable to bias due to
incomplete outcome data. Also, in 17 the researchers had not registered their analysis plans in
advance, so outcomes might have been selectively reported.
Main findings
Of the 32 studies, only half reported total alcohol consumption; for acamprosate and baclofen there
was just one study each, and for topiramate, two. Across all relevant studies, consumption was reduced
significantly more when patients had been allocated to nalmefene, topiramate or baclofen than to a
placebo. This was not the case for naltrexone and acamprosate.
More (21) studies reported the number of days on which patients drank heavily, but for acamprosate
there were none. As with consumption, heavy drinking was reduced significantly more when patients
had been allocated to nalmefene or topiramate than to a placebo, but on this measure baclofen as well
naltrexone had not been shown to be effective. Additionally, compared to a placebo topiramate
significantly increased the number of non-drinking days and nalmefene reduced the number of drinks
per drinking day.
For nalmefene, all estimated effect sizes were small, while baclofen registered a large effect on total
consumption but varied effect sizes on other measures. Topiramate consistently showed medium to
large effect sizes on all drinking outcomes.
In different studies results for naltrexone and topiramate substantially varied. In particular, for
naltrexone one study actually found a placebo significantly more effective.
None of the medications was associated with significantly more deaths or serious adverse events than a
placebo. However, withdrawals from treatment for safety reason were more common among patients
allocated to nalmefene and naltrexone, and adverse events in general more common for naltrexone.
The indirect ‘network’ comparisons had to rely on how the medications compared to a placebo; there
were no direct comparisons between the medications with which to check the validity of these
estimates, and variations between studies were substantial. On this rather unreliable basis, across all
drinking outcomes topiramate seemed superior to nalmefene, naltrexone and acamprosate. In respect
of total consumption, baclofen seemed more effective than naltrexone and acamprosate, but was not
consistently superior on other measures. No significant difference was found across drugs on safety
outcomes, except for withdrawals for safety reasons. These were generally more common on placebos
than on active medications and less common on nalmefene than acamprosate, though there was just
one study for the latter drug.
There was no evidence of differences in drinking outcomes between nalmefene and naltrexone and
their safety profiles were similar.
The authors’ conclusions
While the extension of pharmacotherapy to less severely dependent or non-dependent drinkers is often
advocated as a ‘paradigm shift’, the evidence clearly questions guidelines that promote this approach.
No medication currently has high-quality evidence for moderating drinking among patients suffering
from alcohol use disorders. At best, some have low to medium efficacy relative to a placebo, but across
studies at high risk of bias. Though based on all the available data in the public domain, no evidence
was found of better health outcomes in comparison with a placebo, though no study was of sufficient
size and duration to investigate these outcomes. It should be borne in mind that pharmacological
approaches which might benefit patients by reducing drinking might also harm them due to side effects.
Outcomes which are surrogates for health – such as drinking amounts – should not be relied on as
indicators of health outcomes. Trials should be required which are capable of directly assessing health
outcomes, including adverse effects of medications.
The data suggests that topiramate could be the most effective treatment, with medium to large effect
sizes on most consumption outcomes. However, we can only have very low confidence in this evidence,
which should be considered a prompt to further exploration rather than definitive. In the analysed
studies its safety profile does not appear to differ from that of placebo in respect of adverse events,
serious adverse events, or deaths. However, from other studies we know topiramate can, for example,
cause negative cognitive side effects such as deterioration in verbal fluency, language comprehension,
and working memory. In the analysed studies topiramate may have seemed as safe as other drugs
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Is nalmefene unique in
reducing drinking among
these patients – or only
unique in having gained
authorisation?
because studies were too small, too short, or of insufficient quality to find harmful effects or
events.
Regarding the primary outcome, nalmefene, baclofen and topiramate all reduced total alcohol
consumption more than a placebo, while indirect comparisons suggested that topiramate was
more effective than nalmefene, naltrexone or acamprosate. Nalmefene and naltrexone were
associated with a significant increase in withdrawals from the study and withdrawals for safety
reasons, raising concerns over biased outcomes due patients not being followed up.
Though promoted and authorised for the purposes investigated by the featured analysis, no
evidence was found that nalmefene was superior to the other medications. Relative to a
placebo, naltrexone and acamprosate had yet to be shown to be effective for these purposes. On
baclofen these was only very poor evidence from small studies involving low doses (30–50mg a
day); prescription of high doses (up to 300mg a day) has spread rapidly among alcohol
specialists.
 COMMENTARY It is important to be aware that the limitation to non-detoxified
caseloads who may still be drinking when treatment starts excluded many studies from the
featured analysis, most dramatically in the case of acamprosate, for which just one study was
found despite a more inclusive review having found 22 trials whose results were published up to
September 2013. This limitation may partly account for the lack of data on health-related
outcomes, and means the review’s findings of little evidence of safety differences may simply be
due its limited remit.
The lead author and three of his six co-authors were also among the authors of a review critical
of evidence which in 2013 led the European Medicines Agency to authorise nalmefene to reduce
drinking among heavy drinkers who do not have physical withdrawal symptoms and do not
require immediate detoxification. The decision paved the way to realising the hope that it will
help tackle the bulk of dependent drinking lying below the iceberg-tip of physically dependent
drinkers aiming for abstinence – and at the same time open up for the manufacturer Lundbeck a
huge market previously all but closed to pharmaceutical solutions.
They acknowledged that among this type of patient, those allocated to nalmefene rather than a
placebo drank slightly less, and severity of dependence and alcohol problems also improved
more. However, when they accounted for patients lost to the studies by assuming they
continued to drink as they did at the start of the trials, alcohol consumption outcomes were no
longer significantly better among patients allocated to nalmefene.
Is nalmefene uniquely appropriate for this caseload?
The featured analysis can be understood as an attempt to establish whether nalmefene is
unique in reducing drinking among these types of patients (if indeed it does), or only unique in
a pharmaceutical company having sought and gained authorisation for this purpose. The latter
seems to be the case. Our commentary on the nalmefene analysis had also concluded that
naltrexone’s effects compare well with nalmefene, and noted that in the only head-to-head
comparison – a laboratory study – it led to roughly the same inhibition of drinking.
The significance of these conclusions is that, available as
a generic product, naltrexone is much cheaper. If as the
featured analysis and our earlier analysis found, it is no
less effective and no less safe, across a relevant caseload
there is no clinical justification for spending more to
provide nalmefene, and the main reason for doing so
would boil down the commercial decisions taken by
pharmaceutical companies to seek or not seek
authorisation for reducing drinking among not very heavily dependent drinkers.
Other drugs investigated in the featured review – acamprosate and naltrexone – are two of the
three main medications licensed in the UK for the treatment of alcohol dependence and
endorsed in national guidance for Scotland and England and Wales. Pharmacologists have
argued that these and other medications should be offered to non-dependent problem drinkers
who have not responded well to ‘talking’ therapies, an a practice which would extend their use
into and beyonf nalmefene’s territory.
Though the featured analysis finds no reason to prefer nalmefene, it also finds insufficient
evidence to back prescribing any of the medications for a nalmefene-type caseload. For people
who see dependent drinking as fundamentally a psychological and social problem, prescribing
medications to this caseload represents an unwelcome extension down the severity range of an
opposing vision of the condition as due to neurochemical processes correctable by drugs. Since
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nearly all the trials accompanied medication or placebo with psychosocial support, the
implication of the featured analysis is that none of the medications has definitively
demonstrated its superiority to psychosocial support for this kind of caseload.
Topiramate leads the pack
Topiramate emerged as the most effective medication in reducing drinking across
different measures and as safe as any other. As the authors point out, its apparent safety
may be a function of the limitation to four studies and of the inadequacy of those and
comparison studies for establishing health outcomes. However, this drug seems to have
established itself as one to use when patients are still drinking and may not be aiming
for abstinence, meaning relatively few studies were excluded from the analysis.
A review not limited to a nalmefene-type caseload and published in 2009 concluded that
“topiramate shows great promise as a treatment for alcohol dependence”, with
moderate-size effects (most drugs have small effects) which appear to increase over
time. There have, however, been commonly reported side effects which lead to excessive
withdrawal from treatment, the most disturbing for patients being related to the
depressant effects which come with topiramate’s potent anti-convulsive properties. Also
noted are sensory disturbances including interference with taste and uncomfortable skin
sensations, as well as anorexia and other complaints. These unwanted effects are
considerably reduced if the dose is gradually adjusted up to its maximum, allowing the
reviewers judge that “topiramate has a favourable adverse event profile”. Depressant
effects also mean that the risk of dangerously reduced functioning is greater if the
medication is taken with other depressant drugs, including alcohol.
Reviewers for the British Association for Psychopharmacology acknowledged the drug’s
impacts on drinking, but also noted that its “adverse event profile has likely limited
clinicians using topiramate”. They did however agree that many of these side effects
were due to fast titration to high doses, noting that “slow titration to 300mg/day over
6–8 weeks has been advocated”. Nevertheless, they still felt 300mg a day may be too
high for some patients to tolerate.
Most pertinent for UK policy is the review undertaken for the National Institute for
Health and Clinical Excellence, the basis for its recommendations on which medication
should made available to National Health Service patients. Topiramate is not authorised
or recommended in guidance for the treatment of drinking problems in the UK, and when
they updated their review in 2013, the reviewers saw no reason to change the
judgements which underpinned this decision.
This draft entry is currently subject to consultation and correction by the study authors and other experts.
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